Using specific PET/CT imaging for diagnosing colorectal cancer
Clinical Study of GPA33-specific PET/CT for the Diagnosis of Colorectal Cancer
NA · Huashan Hospital · NCT06203587
This study is testing two new imaging agents to see if they can help doctors better diagnose colorectal cancer in patients.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Huashan Hospital (other) |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT06203587 on ClinicalTrials.gov |
What this trial studies
This study investigates the safety and feasibility of two specific PET/CT imaging agents, [68Ga]Ga-NOTA-WWH347 and [18F]F-H3RESCA-WWH347, in patients with primary and metastatic colorectal cancers. The study aims to evaluate the diagnostic efficacy of these imaging agents, focusing on their sensitivity and specificity. By providing a noninvasive, target-specific method for diagnosing colorectal cancer, this research seeks to enhance clinical diagnosis, differential diagnosis, and treatment planning.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 65 with confirmed colorectal cancer.
Not a fit: Patients with severe hepatic or renal insufficiency or those who have undergone targeted therapy prior to the imaging may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic accuracy for colorectal cancer, facilitating earlier and more effective treatment.
How similar studies have performed: While this approach is innovative, similar studies using PET/CT imaging for cancer diagnosis have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Be between 18 and 65 years of age and of either sex. 2. Patients with colorectal cancer confirmed by puncture or surgical pathology. 3. Written informed consent signed by the subject or legal guardian or caregiver. 4. Willingness and ability to cooperate with all programs of this study. Exclusion Criteria: 1. Severe hepatic or renal insufficiency; 2. Targeted therapy before radiotherapy or PET/CT scan. Renal function: serum creatinine less than or equal to the upper limit of the normal range; 3. Liver function: bilirubin, AST(SGOT)/ALT(SGPT) less than or equal to the upper limit of the normal range. 4. History of serious surgery in the last month. 5. Those who have participated in other clinical trials during the same period.
Where this trial is running
Shanghai
- Huashan Hospital — Shanghai, China (RECRUITING)
Study contacts
- Principal investigator: Fang Xie, PhD — Huashan Hospital
- Study coordinator: Yihui Guan, MD
- Email: guanyihui@hotmail.com
- Phone: 13764308300
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Positron-Emission Tomography, Colorectal Neoplasms